Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
 1 a 20 de 24 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Poluzzi E, Diemberger I, de Ridder M, Koci A, Clo M, Oteri A, Pecchioli S, Bezemer I, Schink T, Ulrichsen SP, Boriani G, Sturkenboom MCJ, De Ponti F, Trifirò G. Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. Eur J Clin Pharmacol 2017;73:1499-510. [Ref.ID 102126]
2.Enlace a cita original Cita con resumen
Oteri A, Mazzaglia G, Pecchioli S, Molokhia M, Ulrichsen SP, Pedersen L, Poluzzi E, De Ponti F, Garbe E, Schink T, Trifirò G. Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs. Br J Clin Pharmacol 2016;82:487-97. [Ref.ID 100690]
3. Cita con resumen
Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, Bégaud B, Pariente A. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ 2016;353:i2231. [Ref.ID 100309]
4. Cita con resumen
Poluzzi E, Piccinni C, Sangiorgi E, Clo M, Tarricone I, Menchetti M, De Ponti F. Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence. Eur J Clin Pharmacol 2013;69:2095-101. [Ref.ID 96640]
5. Cita con resumen
Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, De Ponti F. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013;36:467-79. [Ref.ID 95666]
6.
Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA adverse event reporting system. Drug Saf 2010;33:303-14. [Ref.ID 88227]
7.Enlace a cita original
Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009;18:512-8. [Ref.ID 86355]
8. Cita con resumen
Raschi E, Poluzzi E, Zuliani C, Muller A, Goossens H, De Ponti F. Exposure to antibacterial agents with QT liability in 14 European countries: trends over and 8-year period. Br J Clin Pharmacol 2009;67:88-98. [Ref.ID 84983]
9. Cita con resumen
Poluzzi E, Strahinja P, Vaccheri A, Vargiu A, Silvani MC, Motola D, Marchesini G, De Ponti F, Montanaro N. Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. Br J Clin Pharmacol 2007;63:346-55. [Ref.ID 79456]
10. Cita con resumen
Motola D, De Ponti F, Poluzzi E, Martini N, Rossi P, Silvani MC, Vaccheri A, Montanaro N. An update on the first decade of the European centralized procedure: how many innovative drugs?. Br J Clin Pharmacol 2006;62:610-6. [Ref.ID 78427]
11.
Poluzzi E, Strahinja P, Vargiu A, Chiabrando G, Silvani MC, Motola D, Cellini GS, Vaccheri A, De Ponti F, Montanaro N. nitital treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol 2005;61:603-9. [Ref.ID 75026]
12. Cita con resumen
Motola D, De Ponti F, Rossi P, Martini N, Montanaro N. Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol 2005;59:475-8. [Ref.ID 73535]
13.
Motola D, Vaccheri A, Silvani MC, Poluzzi E, Bottoni A, De Ponti F, Montanaro N. Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol 2004;60:731-8. [Ref.ID 72310]
14.
Tonini M, De Giorgio R, De Ponti F. Progress with novel pharmacological strategies for gastro-oesophageal reflux disease. Drugs 2004;64:347-62. [Ref.ID 69395]
15. Cita con resumen
Poluzzi E, Motola D, Silvani C, De Ponti F, Vaccheri A, Montanaro N. Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement. Eur J Clin Pharmacol 2004;59:825-31. [Ref.ID 68901]
16.
Stanghellini V, De Ponti F, De Giorgio R, Barbara G, Tosetti C, Corinaldesi R. New developments in the treatment of functional dyspepsia. Drugs 2003;63:869-92. [Ref.ID 66413]
17. Cita con resumen
De Ponti F, Poluzzi E, Vaccheri A, Bergman U, Bjerrum L, Ferguson J, Frenz KJ, McManus P, Schubert I, Selke G, Terzis-Vaslamatzis G, Montanaro N. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol 2002;54:171-7. [Ref.ID 63048]
18.
De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263-86. [Ref.ID 61881]
19. Cita con resumen
Poluzzi E, Resi D, Zuccheri P, Motola D, De Ponti F, Vaccheri A, Montanaro N. Use of anti-asthmatic drugs in Italy: analysis of prescriptions in general practice in the light of guidelines for asthma treatment. Eur J Clin Pharmacol 2002;58:55-9. [Ref.ID 61624]
20. Cita con resumen
De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001;57:185-209. [Ref.ID 57523]
Seleccionar todas
 
 1 a 20 de 24 siguiente >>